Cargando…

2551. Assessing Meropenem Concentrations in Children with Septic Shock: Population-Based Pharmacokinetic (PK) Modeling of Meropenem Demonstrates Variability from Acute Kidney (AKI) to Augmented Renal Clearance (ARC)

BACKGROUND: The primary objective of this study was to characterize meropenem (MERO) pharmacokinetics (PK) in critically ill infants and children with septic shock to develop dosing recommendations to achieve therapeutic drug exposure in this complex population with a spectrum of renal function from...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Jennifer, Huynh, Julie, Bradley, John S, Vo, Brandon, Momper, Jeremiah, Capparelli, Edmund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679014/
http://dx.doi.org/10.1093/ofid/ofad500.2168
_version_ 1785150493546250240
author Le, Jennifer
Huynh, Julie
Bradley, John S
Vo, Brandon
Momper, Jeremiah
Capparelli, Edmund
author_facet Le, Jennifer
Huynh, Julie
Bradley, John S
Vo, Brandon
Momper, Jeremiah
Capparelli, Edmund
author_sort Le, Jennifer
collection PubMed
description BACKGROUND: The primary objective of this study was to characterize meropenem (MERO) pharmacokinetics (PK) in critically ill infants and children with septic shock to develop dosing recommendations to achieve therapeutic drug exposure in this complex population with a spectrum of renal function from augmented renal clearance (ARC) to acute kidney injury (AKI). METHODS: Children ≥4 weeks old hospitalized with septic shock requiring fluid resuscitation and pressors, receiving MERO 20 mg/kg IV every 8 hr as standard-of-care, were enrolled and studied prospectively from 2019 to 2023. Population PK modeling was used to derive Bayesian post-hoc PK parameters (NONMEM 7.3). Renal biomarkers (serum creatinine [SCr], cystatin C [CYS], serum neutrophil gelatinase-associated lipocalin [NGAL]) were evaluated as covariates. Estimated glomerular filtration rate (e-GFR) was calculated by the modified Schwartz equation. RESULTS: A total of 304 MERO serum concentrations were included from 26 participants. Median age was 12.6 yr (range 1.2-19.6); weight 38.4 kg (10-98); SCr 0.36 mg/dL (0.09-2.57); CYS 448.9 mg/d (178.3-1824.1), and NGAL 176.05 ng/mL (29.3-1000). Median MERO serum concentration was 11 mcg/mL (range 0.033-217, interquartile range [IQR] 1.873-37.85). A two-compartment model with allometrically scaled weight on clearance (0.75) best described the data. Significant covariates (final model) were e-GFR, CYS, NGAL, age, diagnosis of appendicitis and albumin. Using the final model, the median CL was 0.15 (range 0.05-0.51, interquartile range [IQR] 0.06-0.25) L/hr/kg and V1 0.20 (0.07-0.57, IQR 0.12-0.31) L/kg, with GFR 139 (23-364, IQR 93-204) mL/min/1.73 m2 (Figure). The distribution of MERO concentrations, CL and GFR across quartiles documents wide variations in renal function observed in septic shock, from AKI to ARC (Figure). Meropenem Serum Concentration, Meropenem Renal Clearance, and Glomerular Filtration Rate, by Quartiles [Figure: see text] CONCLUSION: Wide variation in MERO plasma exposure was documented in children with septic shock across the spectrum of renal function. GFR-based dosing recommendations may optimize MERO dosing and improve outcomes in this population. This work was supported by NICHD grant 1 R01 HD095547-01 DISCLOSURES: Edmund Capparelli, PharmD, Melinta: Advisor/Consultant
format Online
Article
Text
id pubmed-10679014
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106790142023-11-27 2551. Assessing Meropenem Concentrations in Children with Septic Shock: Population-Based Pharmacokinetic (PK) Modeling of Meropenem Demonstrates Variability from Acute Kidney (AKI) to Augmented Renal Clearance (ARC) Le, Jennifer Huynh, Julie Bradley, John S Vo, Brandon Momper, Jeremiah Capparelli, Edmund Open Forum Infect Dis Abstract BACKGROUND: The primary objective of this study was to characterize meropenem (MERO) pharmacokinetics (PK) in critically ill infants and children with septic shock to develop dosing recommendations to achieve therapeutic drug exposure in this complex population with a spectrum of renal function from augmented renal clearance (ARC) to acute kidney injury (AKI). METHODS: Children ≥4 weeks old hospitalized with septic shock requiring fluid resuscitation and pressors, receiving MERO 20 mg/kg IV every 8 hr as standard-of-care, were enrolled and studied prospectively from 2019 to 2023. Population PK modeling was used to derive Bayesian post-hoc PK parameters (NONMEM 7.3). Renal biomarkers (serum creatinine [SCr], cystatin C [CYS], serum neutrophil gelatinase-associated lipocalin [NGAL]) were evaluated as covariates. Estimated glomerular filtration rate (e-GFR) was calculated by the modified Schwartz equation. RESULTS: A total of 304 MERO serum concentrations were included from 26 participants. Median age was 12.6 yr (range 1.2-19.6); weight 38.4 kg (10-98); SCr 0.36 mg/dL (0.09-2.57); CYS 448.9 mg/d (178.3-1824.1), and NGAL 176.05 ng/mL (29.3-1000). Median MERO serum concentration was 11 mcg/mL (range 0.033-217, interquartile range [IQR] 1.873-37.85). A two-compartment model with allometrically scaled weight on clearance (0.75) best described the data. Significant covariates (final model) were e-GFR, CYS, NGAL, age, diagnosis of appendicitis and albumin. Using the final model, the median CL was 0.15 (range 0.05-0.51, interquartile range [IQR] 0.06-0.25) L/hr/kg and V1 0.20 (0.07-0.57, IQR 0.12-0.31) L/kg, with GFR 139 (23-364, IQR 93-204) mL/min/1.73 m2 (Figure). The distribution of MERO concentrations, CL and GFR across quartiles documents wide variations in renal function observed in septic shock, from AKI to ARC (Figure). Meropenem Serum Concentration, Meropenem Renal Clearance, and Glomerular Filtration Rate, by Quartiles [Figure: see text] CONCLUSION: Wide variation in MERO plasma exposure was documented in children with septic shock across the spectrum of renal function. GFR-based dosing recommendations may optimize MERO dosing and improve outcomes in this population. This work was supported by NICHD grant 1 R01 HD095547-01 DISCLOSURES: Edmund Capparelli, PharmD, Melinta: Advisor/Consultant Oxford University Press 2023-11-27 /pmc/articles/PMC10679014/ http://dx.doi.org/10.1093/ofid/ofad500.2168 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Le, Jennifer
Huynh, Julie
Bradley, John S
Vo, Brandon
Momper, Jeremiah
Capparelli, Edmund
2551. Assessing Meropenem Concentrations in Children with Septic Shock: Population-Based Pharmacokinetic (PK) Modeling of Meropenem Demonstrates Variability from Acute Kidney (AKI) to Augmented Renal Clearance (ARC)
title 2551. Assessing Meropenem Concentrations in Children with Septic Shock: Population-Based Pharmacokinetic (PK) Modeling of Meropenem Demonstrates Variability from Acute Kidney (AKI) to Augmented Renal Clearance (ARC)
title_full 2551. Assessing Meropenem Concentrations in Children with Septic Shock: Population-Based Pharmacokinetic (PK) Modeling of Meropenem Demonstrates Variability from Acute Kidney (AKI) to Augmented Renal Clearance (ARC)
title_fullStr 2551. Assessing Meropenem Concentrations in Children with Septic Shock: Population-Based Pharmacokinetic (PK) Modeling of Meropenem Demonstrates Variability from Acute Kidney (AKI) to Augmented Renal Clearance (ARC)
title_full_unstemmed 2551. Assessing Meropenem Concentrations in Children with Septic Shock: Population-Based Pharmacokinetic (PK) Modeling of Meropenem Demonstrates Variability from Acute Kidney (AKI) to Augmented Renal Clearance (ARC)
title_short 2551. Assessing Meropenem Concentrations in Children with Septic Shock: Population-Based Pharmacokinetic (PK) Modeling of Meropenem Demonstrates Variability from Acute Kidney (AKI) to Augmented Renal Clearance (ARC)
title_sort 2551. assessing meropenem concentrations in children with septic shock: population-based pharmacokinetic (pk) modeling of meropenem demonstrates variability from acute kidney (aki) to augmented renal clearance (arc)
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679014/
http://dx.doi.org/10.1093/ofid/ofad500.2168
work_keys_str_mv AT lejennifer 2551assessingmeropenemconcentrationsinchildrenwithsepticshockpopulationbasedpharmacokineticpkmodelingofmeropenemdemonstratesvariabilityfromacutekidneyakitoaugmentedrenalclearancearc
AT huynhjulie 2551assessingmeropenemconcentrationsinchildrenwithsepticshockpopulationbasedpharmacokineticpkmodelingofmeropenemdemonstratesvariabilityfromacutekidneyakitoaugmentedrenalclearancearc
AT bradleyjohns 2551assessingmeropenemconcentrationsinchildrenwithsepticshockpopulationbasedpharmacokineticpkmodelingofmeropenemdemonstratesvariabilityfromacutekidneyakitoaugmentedrenalclearancearc
AT vobrandon 2551assessingmeropenemconcentrationsinchildrenwithsepticshockpopulationbasedpharmacokineticpkmodelingofmeropenemdemonstratesvariabilityfromacutekidneyakitoaugmentedrenalclearancearc
AT momperjeremiah 2551assessingmeropenemconcentrationsinchildrenwithsepticshockpopulationbasedpharmacokineticpkmodelingofmeropenemdemonstratesvariabilityfromacutekidneyakitoaugmentedrenalclearancearc
AT capparelliedmund 2551assessingmeropenemconcentrationsinchildrenwithsepticshockpopulationbasedpharmacokineticpkmodelingofmeropenemdemonstratesvariabilityfromacutekidneyakitoaugmentedrenalclearancearc